Clinical trial · Observational
Insulin Resistance in Women With Prolactinoma
Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists
NCT00481299CI-TRIAL-00000743completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma. The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperlipidemia | — | UNRESOLVED | — |
| Insulin Resistance | — | UNRESOLVED | — |
| Prolactinoma | Lactotroph Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 48 Years
Show eligibility criteria text
Inclusion Criteria: * Prolactinoma * Female gender * Premenopausal Exclusion Criteria: * Obesity (BMI ≥ 30 kg/m²) * Diabetes mellitus * Hypertension * GH deficiency * Hypothyroidism * Primary hypogonadism * Adrenal insufficiency * Pituitary surgery
References
Publications (0)
Data not yet available
No reference posted for this study.